Autologous Platform Leverage American CryoStem’s end-to-end autologous adipose-derived MSC platform to offer on-demand, patient-specific regenerative therapies, targeting clinics and hospitals seeking personalized treatment options with reduced immunogenic risk.

Concussion and Long COVID Focus Target collaborations and trials around post-concussion syndrome and Long COVID/PASC to position as a strategic partner for institutions pursuing novel cell-based interventions in high-unmet-need areas with potential for accelerated clinical adoption.

Clinical Partnerships Explore opportunities with existing networks such as the Cell Surgical Network and other surgical/biotech partners to expand access to banking, expansion, and delivery of adipose-derived stem cell therapies.

Small but Nimble Identify mid-market hospitals and specialty clinics with capacity to integrate autologous stem cell workflows, offering scalable cryobanking, processing, and point-of-care delivery as a value proposition for expanding regenerative medicine programs.

Financial and Growth Signals Position CRYO's clinical-stage momentum, strategic advisory additions, and modest revenue footprint as a foundation for partnering discussions with CROs, distributors, and financing partners seeking early-stage regenerative therapy opportunities.